Resource Summary Report

Generated by RRID on Sep 9, 2026

SW900

RRID:CVCL_1731
Type: Cell Line

Proper Citation

RRID:CVCL_1731

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1731

Proper Citation: RRID:CVCL_1731

Description: Cell line SW900 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:924690, PMID:3518877, PMID:6935474, PMID:7459858, PMID:7736387, PMID:12068308, PMID:16187286, PMID:20164919, PMID:20215515, PMID:22460905, PMID:24002593, PMID:24135919, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:29444439, PMID:30894373, PMID:31068700, PMID:31395879

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: TCGA-110-CL cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW900

Synonyms: SW-900, SW 900

Cross References: BTO:BTO_0004611, CLO:CLO_0009202, EFO:EFO_0002374, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-59, BioSample:SAMN03472972, BioSample:SAMN10987793, cancercelllines:CVCL_1731,

Cell_Model_Passport:SIDM01158, ChEMBL-Cells:CHEMBL3308819, ChEMBL-Targets:CHEMBL1075597, Cosmic:724879, Cosmic:933582, Cosmic:1071890, Cosmic:1176591, Cosmic:1608837, Cosmic:1995656, Cosmic:2060528, Cosmic-CLP:724879, DepMap:ACH-000669, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724879, GEO:GSM63352, GEO:GSM784255, GEO:GSM827522, GEO:GSM887680, GEO:GSM888772, GEO:GSM1670515, IARC_TP53:27254, IGRhCellID:SW900, KCLB:30059, LiGeA:CCLE_258, LINCS_LDP:LCL-1593, PharmacoDB:SW900_1548_2019, Progenetix:CVCL_1731, PubChem_Cell_line:CVCL_1731, Wikidata:Q54971217

ID: CVCL_1731

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260905T182524+0000

Ratings and Alerts

No rating or validation information has been found for SW900.

No alerts have been found for SW900.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Ning B, et al. (2026) Upregulation of an Epithelial miRNA Is Associated with Immune Evasion in Progressive Bronchial Premalignant Lesions. Cancer immunology research, 14(4), 689.

Brady MR, et al. (2026) Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. Cancer research, 86(5), 1166.

Liu C, et al. (2025) Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression. Cancer research, 85(13), 2429.

Morel M, et al. (2024) FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. Molecular oncology, 18(3), 762.

Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(17), 3855.

Nguyen T, et al. (2024) TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy. Molecular cancer therapeutics.

Torres-Mart??nez S, et al. (2024) Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. Molecular oncology, 18(1), 190.

Wong KY, et al. (2022) Cancer-associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications. International journal of cancer, 151(8), 1195.

Torres-Ayuso P, et al. (2021) TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. Cancer discovery, 11(6), 1411.

Munck JM, et al. (2021) ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Molecular cancer therapeutics, 20(10), 1757.

Ozkan-Dagliyan I, et al. (2020) Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31(11), 107764.

Takahashi N, et al. (2020) 3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. Molecular cell, 80(5), 828.

Momcilovic M, et al. (2018) The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer cell, 33(5), 905.